In-silico efficacy of potential phytomolecules from Ayurvedic herbs as an adjuvant therapy in management of COVID-19. 2021

Bhanu Kumar, and Ankita Misra, and Satyendra Pratap Singh, and Yogeshwar Vikram Dhar, and Poonam Rawat, and Debprasad Chattopadhyay, and Saroj Kanta Barik, and Sharad Srivastava
Pharmacognosy Division, CSIR-National Botanical Research Institute, Lucknow, U.P. 226001, India.

The recent COVID-19 outbreak caused by SARS-CoV-2 virus has sparked a new spectrum of investigations, research and studies in multifarious directions. Efforts are being made around the world for discovery of effective vaccines/drugs against COVID-19. In this context, Ayurveda, an alternative traditional system of medicine in India may work as an adjuvant therapy in compromised patients. We selected 40 herbal leads on the basis of their traditional applications. The phytomolecules from these leads were further screened through in-silico molecular docking against two main targets of SARS-CoV-2 i.e. the spike protein (S; structural protein) and the main protease (MPRO; non-structural protein). Out of the selected 40, 12 phytomolecules were able to block or stabilize the major functional sites of the main protease and spike protein. Among these, Ginsenoside, Glycyrrhizic acid, Hespiridin and Tribulosin exhibited high binding energy with both main protease and spike protein. Etoposide showed good binding energy only with Spike protein and Teniposide had high binding energy only with main protease. The above phytocompounds showed promising binding efficiency with target proteins indicating their possible applications against SARS-CoV-2. However, these findings need to be validated through in vitro and in vivo experiments with above mentioned potential molecules as candidate drugs for the management of COVID-19. In addition, there is an opportunity for the development of formulations through different permutations and combinations of these phytomolecules to harness their synergistic potential.

UI MeSH Term Description Entries
D008515 Medicine, Ayurvedic The traditional medicine which is based on customs, beliefs, and practices of the Hindu culture. Ayurvedic Medicine,Medicine, Hindu,Siddha Medicine,Hindu Medicine,Medicine, Siddha
D010946 Plants, Medicinal Plants whose roots, leaves, seeds, bark, or other constituent parts possess therapeutic, tonic, purgative, curative or other pharmacologic attributes, when administered to man or animals. Herbs, Medicinal,Medicinal Herbs,Healing Plants,Medicinal Plants,Pharmaceutical Plants,Healing Plant,Herb, Medicinal,Medicinal Herb,Medicinal Plant,Pharmaceutical Plant,Plant, Healing,Plant, Medicinal,Plant, Pharmaceutical,Plants, Healing,Plants, Pharmaceutical
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000086782 Coronavirus 3C Proteases 3C proteases that occur in species of CORONAVIRIDAE. 3C Proteases, Coronavirus,3C-Like Proteinase, Coronavirus,Chymotrypsin-Like Main Protease, Coronavirus,Coronavirus 3C Proteinases,Coronavirus 3CLpro Proteases,Coronavirus 3CLpro Proteinase,M(pro) Protein, Coronavirus,Main Proteinase, Coronavirus,Mpro Protein, Coronavirus,3C Like Proteinase, Coronavirus,3C Proteinases, Coronavirus,3CLpro Proteases, Coronavirus,3CLpro Proteinase, Coronavirus,Chymotrypsin Like Main Protease, Coronavirus,Coronavirus 3C-Like Proteinase,Coronavirus Main Proteinase,Coronavirus Mpro Protein,Proteinase, Coronavirus 3CLpro,Proteinases, Coronavirus 3C
D000093485 COVID-19 Drug Treatment The use of DRUGS to treat COVID19 or its symptoms. COVID-19 Drug Therapy,COVID19 Drug Therapy,COVID19 Drug Treatment,Coronavirus Disease 2019 Drug Treatment,Coronavirus Disease-19 Drug Treatment,COVID 19 Drug Therapy,COVID 19 Drug Treatment,COVID-19 Drug Therapies,COVID19 Drug Therapies,COVID19 Drug Treatments,Coronavirus Disease 19 Drug Treatment,Drug Therapy, COVID-19,Drug Therapy, COVID19,Therapy, COVID-19 Drug,Therapy, COVID19 Drug,Treatment, COVID-19 Drug
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking
D028321 Plant Preparations Material prepared from plants. Herbal Preparations,Herbal Preparation,Plant Preparation,Preparation, Plant
D064370 Spike Glycoprotein, Coronavirus A class I viral fusion protein that forms the characteristic spikes, or peplomers, found on the viral surface that mediate virus attachment, fusion, and entry into the host cell. During virus maturation, it is cleaved into two subunits: S1, which binds to receptors in the host cell, and S2, which mediates membrane fusion. Spike Glycoprotein, Bovine Coronavirus,Spike Glycoproteins, Coronavirus,E2 Spike Glycoprotein, Coronavirus,Glycoprotein S, Coronavirus,Spike Glycoprotein S1, Coronavirus,Spike Protein S2, Coronavirus,Spike Protein, Coronavirus,Coronavirus Spike Glycoprotein,Coronavirus Spike Protein

Related Publications

Bhanu Kumar, and Ankita Misra, and Satyendra Pratap Singh, and Yogeshwar Vikram Dhar, and Poonam Rawat, and Debprasad Chattopadhyay, and Saroj Kanta Barik, and Sharad Srivastava
April 2021, Chinese journal of integrative medicine,
Bhanu Kumar, and Ankita Misra, and Satyendra Pratap Singh, and Yogeshwar Vikram Dhar, and Poonam Rawat, and Debprasad Chattopadhyay, and Saroj Kanta Barik, and Sharad Srivastava
January 2020, Bratislavske lekarske listy,
Bhanu Kumar, and Ankita Misra, and Satyendra Pratap Singh, and Yogeshwar Vikram Dhar, and Poonam Rawat, and Debprasad Chattopadhyay, and Saroj Kanta Barik, and Sharad Srivastava
January 2022, Biophysics,
Bhanu Kumar, and Ankita Misra, and Satyendra Pratap Singh, and Yogeshwar Vikram Dhar, and Poonam Rawat, and Debprasad Chattopadhyay, and Saroj Kanta Barik, and Sharad Srivastava
August 2022, Phytomedicine plus : international journal of phytotherapy and phytopharmacology,
Bhanu Kumar, and Ankita Misra, and Satyendra Pratap Singh, and Yogeshwar Vikram Dhar, and Poonam Rawat, and Debprasad Chattopadhyay, and Saroj Kanta Barik, and Sharad Srivastava
March 2021, Journal of molecular modeling,
Bhanu Kumar, and Ankita Misra, and Satyendra Pratap Singh, and Yogeshwar Vikram Dhar, and Poonam Rawat, and Debprasad Chattopadhyay, and Saroj Kanta Barik, and Sharad Srivastava
October 2021, Current microbiology,
Bhanu Kumar, and Ankita Misra, and Satyendra Pratap Singh, and Yogeshwar Vikram Dhar, and Poonam Rawat, and Debprasad Chattopadhyay, and Saroj Kanta Barik, and Sharad Srivastava
May 2022, Journal of molecular modeling,
Bhanu Kumar, and Ankita Misra, and Satyendra Pratap Singh, and Yogeshwar Vikram Dhar, and Poonam Rawat, and Debprasad Chattopadhyay, and Saroj Kanta Barik, and Sharad Srivastava
June 2023, Drug metabolism and personalized therapy,
Bhanu Kumar, and Ankita Misra, and Satyendra Pratap Singh, and Yogeshwar Vikram Dhar, and Poonam Rawat, and Debprasad Chattopadhyay, and Saroj Kanta Barik, and Sharad Srivastava
September 2023, Drug metabolism and personalized therapy,
Bhanu Kumar, and Ankita Misra, and Satyendra Pratap Singh, and Yogeshwar Vikram Dhar, and Poonam Rawat, and Debprasad Chattopadhyay, and Saroj Kanta Barik, and Sharad Srivastava
July 2020, International journal of clinical pharmacology and therapeutics,
Copied contents to your clipboard!